Menopause & midlife

Testosterone for Women: The Libido Evidence

Save

Testosterone modestly helps one thing in women: low sexual desire in postmenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). A global consensus of medical societies found a real but moderate benefit for desire and arousal at female-range doses, and little evidence it improves mood, energy, or bone. Low desire has many causes worth exploring first.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Does testosterone actually improve libido in women?

Testosterone can raise sexual desire in a defined group of women, and the effect is real but modest. The 2019 Global Consensus Position Statement, endorsed by international menopause and endocrine societies, concluded that the only evidence-based use is treating hypoactive sexual desire disorder in postmenopausal women 1. In pooled trials, testosterone improved sexual desire, arousal, orgasm, and satisfaction compared with placebo 1.

In practical terms, that averaged out to roughly one extra satisfying sexual encounter a month in the trials, a modest rather than transformative change. A separate Cochrane review found that adding androgens to hormone therapy improved sexual function scores in postmenopausal women 2. The benefit is meaningful for the right person but does not extend to women without a genuine desire disorder.

Why do testosterone levels fall, and does that explain low desire?

Testosterone in women declines gradually with age rather than dropping sharply at menopause. Levels fall by roughly half, about 50%, between about age 20 and age 40, so by the time desire concerns surface in perimenopause, no single hormone shift usually explains them 1. Surgical removal of the ovaries can lower testosterone more abruptly, which is one reason desire may change after that surgery.

Estrogen loss matters too: vaginal dryness and pain from genitourinary syndrome of menopause can dampen desire on their own, and the North American Menopause Society notes these are treated with local estrogen rather than testosterone 4. Our overview of testosterone levels in women explains why lab numbers are hard to interpret. Low desire is usually layered, not a single deficiency.

What are the limits and risks of the evidence?

Evidence for testosterone in women is genuinely limited in scope and length. Most trials ran for 6 to 12 months, so long-term effects on the breast, heart, and other outcomes are not well established 1. Because no product is approved for women in most countries, studies used male preparations at reduced doses, and the consensus recommends against compounded or pellet forms that can push levels too high 1.

At female-range doses, side effects are usually mild, such as acne or extra hair, and reverse when treatment stops; supraphysiologic doses risk deeper voice or hair changes that may not reverse 1. A separate Cochrane review echoed that sexual-function benefits come with uncertainty about long-term safety 2. Standard menopausal hormone therapy, by contrast, is estrogen with a progestogen and does not include testosterone 5.

When low desire questions need a specialist

A clinician is essential for sorting out whether testosterone is even the right question. Because low desire usually has several contributors, a gynecologist, menopause specialist, or primary care clinician can evaluate mood, relationship factors, medications, sleep, and pain before considering hormones 3.

If a desire disorder is confirmed, they can discuss whether a female-range testosterone trial is reasonable and how it would be monitored, which our companion guide on how testosterone is prescribed and monitored covers. Medication side effects on desire are common, and our piece on antidepressants and sexual side effects explains one frequent cause. Gale can help you prepare for that conversation.

Common questions

The evidence does not support it. A global consensus of medical societies found a benefit only for sexual desire in postmenopausal women with a diagnosed desire disorder, and not enough evidence for energy, mood, or general well-being. Marketing that promises broader benefits runs ahead of the science.

There is not enough evidence to recommend it. The research supporting testosterone for low desire was done in postmenopausal women, so consensus guidance does not extend the recommendation to premenopausal women. Low desire at any age deserves a full evaluation of contributing factors first.

Modestly. In pooled trials, women with a desire disorder reported improved desire, arousal, and satisfaction versus placebo, averaging around one additional satisfying sexual encounter a month. That is meaningful for the right person but is not a dramatic change, and it does not help women without a desire disorder.

Often not on its own. Desire is shaped by mood, relationships, medications, sleep, pain, and estrogen-related vaginal changes. No blood test reliably defines testosterone deficiency in women, so clinicians look at the whole picture rather than a single hormone level.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When low desire deserves a closer look

  • —Low desire that causes you distress or strains a relationship is a reason to seek an evaluation with a clinician.
  • —Pain during sex, vaginal dryness, or bleeding is a reason to seek gynecologic review rather than starting a hormone on your own.
  • —Low mood, loss of interest in most activities, or thoughts of self-harm are reasons to seek mental health support; in the US you can call or text 988 for the Suicide and Crisis Lifeline.
  • —New acne, unwanted hair growth, or voice changes while using testosterone are a reason to seek clinician review of your dose.

This article is general health education, not medical advice. Whether testosterone is appropriate for low desire is a decision to make with a gynecologist, menopause specialist, or primary care clinician.

References

  1. 1.Davis SR, et al. (International consensus, endorsed by The Endocrine Society and International Menopause Society) (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2019-01603 ✓Global Consensus Position Statement that the only evidence-based indication for testosterone in women is HSDD in postmenopausal women, with a modest benefit for desire, arousal, and orgasm, no evidence for mood or energy, age-related decline in levels, no diagnostic blood threshold, and advice against compounded or pellet forms.
  2. 2.Nastri CO, Lara LA, Ferriani RA, et al. (2013). Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD009672.pub2 ✓Cochrane review finding that hormone therapy, including added androgens, improved sexual function scores in postmenopausal women, with uncertainty about long-term safety.
  3. 3.American College of Obstetricians and Gynecologists (2019). Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003324 ✓ACOG practice bulletin describing evaluation of female sexual dysfunction, the prevalence of distressing sexual concerns, and distinguishing hypoactive sexual desire disorder from other causes before treatment.
  4. 4.The North American Menopause Society (Menopause Society) (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000001609 ✓NAMS position that genitourinary syndrome of menopause causes dryness and pain that can dampen desire and are treated with local vaginal estrogen rather than testosterone.
  5. 5.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓NAMS 2022 position framing standard menopausal hormone therapy as estrogen with a progestogen, which does not include testosterone.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library